This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Bacterial infection

Toll-like receptor 2
(TLR2); CD14

Patient sample and mouse studies identified CD14-targeting peptides that could help treat bacterial infections. In mouse models for Gram-positive and Gram-negative bacterial peritonitis, CD14-binding peptides derived from leucine-rich repeat motifs in TLR2 accelerated bacterial clearance compared with saline. In whole blood samples from patients with sepsis-associated immunosuppression, two of the peptides restored chemokine responses to a challenge with bacteria and bacteria-derived antigens. Next steps could include testing the antibacterial effects in additional models of bacterial infection.

Implicit Biosciences Pty. Ltd.'s IC14, an antibody targeting CD14, is in Phase II testing to treat acute lung injury.

SciBX 6(23); doi:10.1038/scibx.2013.580
Published online June 13, 2013

Patent and licensing status unavailable

Raby, A.-C. et al. Sci. Transl. Med.; published online May 15, 2013;
doi:10.1126/scitranslmed.3005544
Contact: Mario Labéta, Cardiff University, Cardiff, U.K.
e-mail:
wmdmol@cardiff.ac.uk

Contact: Ann-Catherine Raby, same affiliation as above
e-mail:
rabya@cardiff.ac.uk